NasdaqGS:PACBLife Sciences
Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives
Pacific Biosciences of California (PACB) has just posted its FY 2025 numbers, with Q4 revenue at US$44.6 million and a basic EPS loss of US$0.13 set against trailing twelve month revenue of US$160.0 million and a TTM basic EPS loss of US$1.82. Over the past six reported quarters, the company has seen quarterly revenue move between US$37.2 million and US$44.6 million, while basic EPS has ranged from a small profit of US$0.01 in FY 2024 Q4 to a loss of US$1.44 in FY 2025 Q1. This leaves...